Research Reports Initiated on Healthcare Stocks BELLUS Health, Resverlogix, Helius Medical Technologies, and IntelliPharmaCeutics International

LONDON, UK / ACCESSWIRE / March 29, 2017 / Active Wall St. announces the list of stocks for today’s research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected stocks trading on the Toronto Exchange and belonging under the Biotechnology industry. Companies recently under review include BELLUS Health, Resverlogix, Helius Medical Technologies, and IntelliPharmaCeutics International. Get all of our free research reports by signing up at:

http://www.activewallst.com/register/

At the close of the Canadian markets on Tuesday, March 28, 2017, the Toronto Exchange Composite index ended the trading session at 15,598.57, 0.60% higher from its previous closing price.

The Healthcare Index was in the red, closing the day at 67.85, down 0.29%.

Active Wall St. has initiated research reports on the following equities: BELLUS Health Inc. (TSX: BLU), Resverlogix Corporation (TSX: RVX), Helius Medical Technologies Inc. (TSX: HSM), and IntelliPharmaCeutics International Inc. (TSX: IPCI). Register with us now for your free membership and research reports at:

http://www.activewallst.com/register/

BELLUS Health Inc.

Laval, Canada-based BELLUS Health Inc.’s stock declined 1.82%, to finish Tuesday’s session at $0.27 with a total volume of 49,820 shares traded. Shares of the Company, which together with its subsidiaries, focuses on the research and development of drugs for rare diseases, are trading below its 50-day moving average. BELLUS Health’s 50-day moving average of $0.28 is above its 200-day moving average of $0.27. See our research report on BLU.TO at:

http://www.activewallst.com/register/

Resverlogix Corp.

On Tuesday, shares in Calgary, Canada headquartered Resverlogix Corp. recorded a trading volume of 40,140 shares. The stock ended the day 3.60% higher at $2.30. Resverlogix’s stock has surged 13.30% in the last one month and 37.72% in the previous three months. Furthermore, the stock has rallied 82.54% in the past one year. Shares of the Company, which develops small molecule therapeutics for Bromodomain and ExtraTerminal (BET) inhibition, are trading above its 50-day and 200-day moving averages. The stock’s 50-day moving average of $2.04 is above its 200-day moving average of $1.89. The complimentary research report on RVX.TO at:

http://www.activewallst.com/register/

Helius Medical Technologies Inc.

On Tuesday, shares in Newtown, Pennsylvania headquartered Helius Medical Technologies Inc. ended the session 0.48% higher at $2.09 with a total volume of 23,715 shares traded. Helius Medical Technologies’ shares have gained 12.97% in the last three months and 90.00% in the previous one year. Shares of the Company, which operates as a medical technology company focused on neurological wellness, are trading above its 200-day moving average. Furthermore, the stock’s 50-day moving average of $2.14 is greater than its 200-day moving average of $1.94. Register for free and access the latest research report on HSM.TO at:

http://www.activewallst.com/register/

IntelliPharmaCeutics International Inc.

Toronto, Canada-based IntelliPharmaCeutics International Inc.’s stock closed the day 2.55% higher at $3.22. The stock recorded a trading volume of 4,100 shares. IntelliPharmaCeutics International’s shares have advanced 2.55% in the last one month. Shares of the Company, which develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in Canada, are trading above its 50-day moving average of $3.07. Get free access to your research report on IPCI.TO at:

http://www.activewallst.com/register/

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 458428